Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 05 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.55 Insider Own1.71% Shs Outstand188.56M Perf Week21.13%
Market Cap97.67M Forward P/E- EPS next Y-0.69 Insider Trans-3.62% Shs Float187.51M Perf Month-6.91%
Income-293.67M PEG- EPS next Q-0.20 Inst Own75.99% Short Float / Ratio4.27% / 4.81 Perf Quarter-10.65%
Sales88.26M P/S1.11 EPS this Y27.23% Inst Trans-4.40% Short Interest8.01M Perf Half Y-15.96%
Book/sh0.84 P/B0.61 EPS next Y51.83% ROA-48.01% Target Price2.75 Perf Year-83.21%
Cash/sh1.95 P/C0.26 EPS next 5Y-7.30% ROE-102.75% 52W Range0.41 - 3.19 Perf YTD-77.35%
Dividend- P/FCF- EPS past 5Y-25.98% ROI-76.24% 52W High-83.95% Beta0.85
Dividend %- Quick Ratio7.37 Sales past 5Y37.56% Gross Margin62.93% 52W Low24.09% ATR0.04
Employees216 Current Ratio7.66 Sales Q/Q2.20% Oper. Margin-164.80% RSI (14)52.04 Volatility7.91% 10.12%
OptionableYes Debt/Eq1.54 EPS Q/Q23.51% Profit Margin-332.73% Rel Volume0.39 Prev Close0.51
ShortableYes LT Debt/Eq1.42 EarningsNov 07 AMC Payout- Avg Volume1.66M Price0.51
Recom3.00 SMA204.22% SMA50-0.64% SMA200-30.66% Volume649,061 Change-0.58%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Resumed JP Morgan Underweight
Nov-09-23Upgrade TD Cowen Market Perform → Outperform
May-10-23Upgrade Jefferies Underperform → Hold $1.50 → $1
Feb-24-23Downgrade Jefferies Hold → Underperform $3.20 → $1.50
Aug-08-22Downgrade JP Morgan Neutral → Underweight
May-31-22Resumed Jefferies Hold $12 → $4
Apr-18-22Downgrade Goldman Neutral → Sell $3
Mar-15-22Downgrade Mizuho Buy → Neutral $35 → $8
Mar-15-22Downgrade Cowen Outperform → Market Perform
Mar-14-22Downgrade William Blair Outperform → Mkt Perform
Nov-09-23 08:39AM
Nov-08-23 11:47AM
Nov-07-23 05:28PM
Oct-31-23 06:00PM
10:02AM Loading…
Oct-26-23 10:02AM
Oct-23-23 10:08AM
Oct-13-23 08:30AM
Oct-02-23 09:00AM
Sep-27-23 09:00AM
Sep-14-23 07:54AM
Sep-13-23 09:00AM
Sep-07-23 11:31AM
Sep-06-23 06:00PM
Aug-17-23 07:02PM
09:25AM Loading…
Aug-09-23 09:25AM
Aug-08-23 05:30PM
Aug-07-23 10:23AM
Aug-01-23 06:00PM
Jul-24-23 03:48AM
Jul-16-23 08:49AM
Jun-12-23 06:00PM
Jun-08-23 12:55PM
May-10-23 11:28AM
06:45PM Loading…
May-09-23 06:45PM
May-08-23 09:29AM
May-04-23 10:00AM
May-02-23 10:01AM
Apr-27-23 08:30AM
Apr-19-23 08:38AM
Apr-17-23 05:00PM
Apr-16-23 06:30AM
Apr-13-23 10:59AM
Apr-11-23 08:57AM
Apr-10-23 10:07AM
Apr-02-23 08:27AM
Mar-30-23 11:30AM
Mar-29-23 05:44PM
Mar-24-23 12:00PM
Mar-22-23 09:35AM
Mar-14-23 03:43AM
Feb-28-23 05:15PM
Feb-24-23 10:23AM
Feb-23-23 06:20PM
Jan-09-23 09:04AM
Jan-04-23 09:00AM
Dec-12-22 10:05AM
Dec-05-22 08:00AM
Nov-10-22 09:05AM
Nov-09-22 09:00AM
Nov-04-22 12:35PM
Nov-03-22 06:35PM
Oct-28-22 10:00AM
Oct-27-22 10:02AM
Oct-25-22 06:00PM
Oct-24-22 07:55AM
Oct-11-22 05:13PM
Oct-07-22 03:42PM
Sep-07-22 01:15AM
Aug-21-22 09:57AM
Aug-16-22 08:30AM
Aug-05-22 12:11PM
Aug-04-22 06:15PM
Jul-26-22 06:00PM
Jul-14-22 06:01AM
Jul-01-22 06:30AM
May-27-22 08:00AM
May-16-22 02:09PM
May-06-22 10:07AM
May-05-22 05:55PM
May-04-22 08:15AM
Apr-28-22 03:02PM
Apr-27-22 12:00PM
Apr-26-22 09:19AM
Apr-25-22 06:00PM
Apr-22-22 08:30AM
Apr-20-22 12:54PM
Apr-18-22 05:25PM
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROBIN HOWARD WPresident & CEONov 17Sale0.4919,8779,740899,922Nov 20 08:58 PM
Zalevsky JonathanChief R&D OfficerNov 17Sale0.499,6464,727274,039Nov 20 09:02 PM
Wilson Mark AndrewChief Legal OfficerNov 17Sale0.497,1793,518243,780Nov 20 09:00 PM
Curet MyriamDirectorSep 18Sale0.694,3593,00827,418Sep 20 08:09 PM
Ajer Jeffrey RobertDirectorSep 18Sale0.694,3593,00834,153Sep 20 08:06 PM
ROBIN HOWARD WPresident & CEOAug 16Sale0.7819,99815,598919,799Aug 17 08:06 PM
Zalevsky JonathanChief R&D OfficerAug 16Sale0.789,7037,568283,685Aug 17 08:08 PM
Wilson Mark AndrewChief Legal OfficerAug 16Sale0.787,2215,632250,959Aug 17 08:07 PM
WHITFIELD ROY ADirectorJun 14Sale0.5730,00017,100216,250Jun 15 06:26 PM
ROBIN HOWARD WPresident & CEOMay 16Sale0.7220,36114,660939,797May 17 08:27 PM
Zalevsky JonathanChief R&D OfficerMay 16Sale0.729,7917,050293,388May 17 08:29 PM
Wilson Mark AndrewChief Legal OfficerMay 16Sale0.727,5435,431257,680May 17 08:28 PM
ROBIN HOWARD WPresident & CEOFeb 16Sale3.0019,63558,905960,158Feb 17 08:57 PM
Zalevsky JonathanChief R&D OfficerFeb 16Sale3.0010,48431,452303,179Feb 17 09:00 PM
Thomsen Jillian B.Chief Financial OfficerFeb 16Sale3.0010,26730,801313,497Feb 17 08:58 PM
Wilson Mark AndrewChief Legal OfficerFeb 16Sale3.008,27524,825265,223Feb 17 08:59 PM